Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate

Journal of Immunology

Volumn 178, Issue 10, 2007, Pages 6596-6603

  Forthal, Donald N ^a,c   Gilbert, Peter B ^b   Landucci, Gary ^a   Phan, Tran ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; FC RECEPTOR; GLYCOPROTEIN GP 120; RECOMBINANT VACCINE;

ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; DNA POLYMORPHISM; DONOR; EFFECTOR CELL; FEMALE; GENE LOCUS; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINATION; VIRUS INHIBITION; VIRUS STRAIN;

EID: 34248168722     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.10.6596     Document Type: Article

References (46)

1. Hofmann-Lehmann, R., J. Vlasak, R. A. Rasmussen, B. A. Smith, T. W. Baba, V. Liska, F. Ferrantelli, D. C. Montefiori, H. M. McChire, D. C. Anderson, et al. 2001. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75: 7470-7480.
2. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73: 4009-4018.
3. Mascola, J. R., M. G. Lewis, T. C. VanCott, G. Stiegler, H. Katinger, M. Seaman, K. Beaudry, D. H. Barouch, B. Korioth-Schmitz, G. Krivulka, et al. 2003. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J. Virol. 77: 10348-10356.
4. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6: 207-210.
5. Parren, P. W., P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, and D. R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75: 8340-8347.
6. Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M. W. Cho, and M. A. Martin. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med 5: 204-210.
7. Van Rompay, K. K., C. J. Berardi, S. Dillard-Telm, R. P. Tarara, D. R. Canfield, C. R. Valverde, D. C. Montefiori, K. S. Cole, R. C. Montelaro, C. J. Miller, and M. L. Marthas. 1998. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177: 1247-1259.
8. Someya, K., D. Cecilia, Y. Ami, T. Nakasone, K. Matsuo, S. Burda, H. Yamamoto, N. Yoshino, M. Kaizu, S. Ando, et al. 2005. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol. 79: 1452-1462.
9. Buckner, C., L. G. Gines, C. J. Saunders, L. Vojtech, I. Srivastava, A. Gettie, R. Bohm, J. Blanchard, S. W. Barnett, J. T. Safrit, and L. Stamatatos. 2004. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320: 167-180.
10. Forthal, D. N., and G. Landucci. 1998. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J. Immunol. Methods 220: 129-138.
11. Forthal, D. N., G. Landucci, and E. S. Daar. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75: 6953-6961.
12. Holl, V., M. Peressin, T. Decoville, S. Schmidt, S. Zolla-Pazner, A. M. Aubertin, and C. Moog. 2006. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type I replication in macrophages and immature dendritic cells. J. Virol. 80: 6177-6181.
13. Forthal, D. N., G. Landucci, K. S. Cole, M. Marthas, J. C. Becerra, and K. Van Rompay. 2006. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 80: 9217-9225.
14. Flynn, N. M., D. N. Forthal, C. D. Harro, F. N. Judson, K. H. Mayer, M. F. Para, and the rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
15. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, K. Choopanya, and Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194: 1661-1671.
16. Gilbert, P. B., M. L. Peterson, D. Follmann, M. G. Hudgens, D. P. Francis, M. Gurwith, W. L. Heyward, D. V. Jobes, V. Popovic, S. G. Self, et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191: 666-677.
17. Robertson, G. A., B. M. Kostek, W. A. Schleif, J. A. Lewis, and E. A. Emini. 1988. A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity. J. Virol. Methods 20: 195-202.
18. Dall'Ozzo, S., C. Andres, P. Bardos, H. Watier, and G. Thibault. 2003. Rapid single-step FCGR3A genotyping based on SYBR green I fluorescence in realtime multiplex allele-specific PCR. J. Immunol. Methods 277: 185-192.
19. Borgan, O., B. Langholz, S. O. Samuelsen, L. Goldstein, and J. Pogoda. 2000. Exposure stratified case-cohort designs. Lifetime Data Anal. 6: 39-58.
20. Dijstelbloem, H. M., J. G. van de Winkel, and C. G. Kallenberg. 2001. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 22: 510-516.
21. Warmerdam, P. A., J. G. van de Winkel, A. Vlug, N. A. Westerdaal, and P. J. Capel. 1991. A single amino acid in the second Ig-like domain of the human Feγ receptor II is critical for human IgG2 binding. J. Immunol. 147: 1338-1343.
22. Parren, P. W., P. A. Warmerdam, L. C. Boeije, J. Arts, N. A. Westerdaal, A. Vlug, P. J. Capel, L. A. Aarden, and J. G. van de Winkel. 1992. On the interaction of IgG subclasses with the low affinity Fc γRIIa (CD32) on human monocytes, neutrophils, and platelets: analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90: 1537-1546.
23. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch. 1994. FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 76: 519-529.
24. Vance, B. A., T. W. Huizinga, K. Wardwell, and P. M. Guyre. 1993. Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells. J. Immunol. 151: 6429-6439.
25. Clark, M. R., S. B. Clarkson, P. A. Ory, N. Stollman, and I. M. Goldstein. 1989. Molecular basis for a polymorphism involving Fc receptor II on human monocytes. J. Immunol. 143: 1731-1734.
26. Ravetch, J. V., and B. Perussia. 1989. Alternative membrane forms of FcγRIII(CD16) on human natural killer cells and neutrophils: cell type-specific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med. 170: 481-497.
27. Wu, J., J. C. Edberg, P. B. Redecha, V. Bansal, P. M. Guyre, K. Coleman, J. E. Salmon, and R. P. Kimberly. 1997. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100: 1059-1070.
28. Koene, H. R., M. Kleijer, J. Algra, D. Roos, A. E. von dem Borne, and M. de Haas. 1997. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/ R/H phenotype. Blood 90: 1109-1114.
29. van der Pol, W. L., M. D. Jansen, W. J. Sluiter, B. van de Sluts, F. G. Leppers-van de Straat, T. Kobayashi, R. G. Westendorp, T. W. Huizinga, and J. G. van de Winkel. 2003. Evidence for non-random distribution of Fcγ receptor genotype combinations. Immunogenetics 55: 240-246.
30. Forthal, D. N., G. Landucci, M. K. Gorny, S. Zolla-Pazner, and W. E. Robinson, Jr. 1995. Functional activities of 20 human immunodeficiency virus type 1 (HTV-1)-specific human monoclonal antibodies. AIDS Res. Hum Retroviruses 11: 1095-1099.
31. Alsmadi, O., and S. A. Tilley. 1998. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities. J. Virol. 72: 286-293.
32. Gomez-Roman, V. R., L. J. Patterson, D. Venzon, D. Liewehr, K. Aldrich, R. Florese, and M. Robert-Guroff. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174: 2185-2189.
33. van Sorge, N. M., W. L. van der Pol, and J. G. van de Winkel. 2003. FcγR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61: 189-202.
34. Fernandez, N., M. Renedo, C. Garcia-Rodriguez, and M. Sanchez Crespo. 2002. Activation of monocytic cells through Fcγ receptors induces the expression of macrophage-inflammatory protein (MIP)-1α, MIP-1β, and RANTES. J. Immunol. 169: 3321-3328.
35. + blood monocytes exhibits features of tissue macrophages. Eur. J. Immunol. 23: 2053-2058.
36. Radstake, T. R., A. W. van Lieshout, P. L. van Riel, W. B. van den Berg, and G. J. Adema. 2005. Dendritic cells, Fcγ receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann. Rheum. Dis. 64: 1532-1538.
37. Borrego, F., A. Lopez-Beltran, J. Pena, and R. Solana. 1994. Downregulation of Fcγ receptor IIIAα (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. Cell. Immunol. 158: 208-217.
38. Bharadwaj, D., M. P. Stein, M. Volzer, C. Mold, and T. W. Du Clos. 1999. The major receptor for C-reactive protein on leukocytes is Fcγ receptor II. J. Exp. Med. 190: 585-590.
39. Bodman-Smith, K. B., R. E. Gregory, P. T. Harrison, and J. G. Raynes. 2004. FcγRIIa expression with FcγRI results in C-reactive protein- and IgG-mediated phagocytosis. J. Leukocyte BioL. 75: 1029-1035.
40. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758.
41. Niwa, R., S. Hatanaka, E. Shoji-Hosaka, M. Sakurada, Y. Kobayashi, A. Uehara, H. Yokoi, K. Nakamura, and K. Shitara. 2004. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcγRIIIa functional polymorphism. Clin. Cancer Res. 10: 6248-6255.
42. Brouwer, K. C., R. B. Lal, L. B. Mirel, C. Yang, A. M. van Eijk, J. Ayisi, J. Otieno, B. L. Nahlen, R. Steketee, A. A. Lal, and Y. P. Shi. 2004. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 18: 1187-1194.
43. Chen, J. Y., C. M. Wang, J. M. Wu, H. H. Ho, and S. F. Luo. 2006. Association of rheumatoid factor production with FcγRIIIa polymorphism in Taiwanese rheumatoid arthritis. Clin. Exp. Immunol. 144: 10-16.
44. 2 antibodies to Plasmodium falciparum merozoite antigens in Gabonese children. J. Infect. Dis. 192: 1975-1980.
45. Sarvas, H., P. Vesterinen, and O. Makela. 2002. Serum IgG2 concentration is associated with Gm-allotypes of IgG2 but not with the R131H polymorphism of human Fcγ receptor type IIa. J. Clin. Immunol. 22: 92-97.
46. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1: the National Institute of Allergy and Infectious Diseases AIDS vaccine evaluation group. J. Infect. Dis. 173: 340-348.